UniProtKB/SwissProt variant VAR

Variant information

Variant position:

130

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Valine (V) at position 130 (G130V, p.Gly130Val).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from glycine (G) to medium size and hydrophobic (V)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In FRDA.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs104894107 [ dbSNP | Ensembl ]

Sequence information

Variant position:

130

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

210

The length of the canonical sequence.

Location on the sequence:

FEDLADKPYTFEDYDVSFGS G VLTVKLGGDLGTYVINKQTP

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FEDLADKPYTFEDYDVSFGSGVLTVKLGGDLGTYVINKQTP

Mouse                         FEDLADKPYTLEDYDVSFGDGVLTIKLGGDLGTYVINKQTP

Rat                           FEDLADKPYTLKDYDVSFGDGVLTIKLGGDLGTYVINKQTP

Bovine                        FEDLADKPYTFEDYDVSFGSGVLTVKLGGDLGTYVINKQTP

Caenorhabditis elegans        FDQIADSFPVSEQFDVSHAMGVLTVNVSKSVGTYVINKQSP

Drosophila                    FEELTENASELQGTDVAYSDGVLTVNLGGQHGTYVINRQTP

Slime mold                    LEILSEA-NTCEGFEVEGNDGVLTIIVGNK-GTYVINKQTP

Baker's yeast                 LEELSEAHPDCIP-DVELSHGVMTLEIPAF-GTYVINKQPP

Fission yeast                 FEDLLEEVGK-KDYDIQYANGVITLMLGEK-GTYVINKQPP

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	42 – 210	Frataxin intermediate form
Chain	56 – 210	Frataxin(56-210)
Chain	78 – 210	Frataxin(78-210)
Chain	81 – 210	Frataxin mature form

Literature citations

Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion.
Bidichandani S.I.; Ashizawa T.; Patel P.I.;
Am. J. Hum. Genet. 60:1251-1256(1997)
Cited for: VARIANTS FRDA VAL-130 AND PHE-154;

The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene.
Forrest S.M.; Knight M.; Delatycki M.B.; Paris D.; Williamson R.; King J.; Yeung L.; Nassif N.; Nicholson G.A.;
Neurogenetics 1:253-257(1998)
Cited for: VARIANTS FRDA VAL-130; CYS-165 AND PHE-182;

Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes.
Cossee M.; Duerr A.; Schmitt M.; Dahl N.; Trouillas P.; Allinson P.; Kostrzewa M.; Nivelon-Chevallier A.; Gustavson K.-H.; Kohlschuetter A.; Mueller U.; Mandel J.-L.; Brice A.; Koenig M.; Cavalcanti F.; Tammaro A.; de Michele G.; Filla A.; Cocozza S.; Labuda M.; Montermini L.; Poirier J.; Pandolfo M.;
Ann. Neurol. 45:200-206(1999)
Cited for: VARIANTS FRDA TYR-122 AND VAL-130;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q16595: Variant p.Gly130Val